Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkA

TrkA

Brief Information

Name:Nerve growth factor receptor Trk-A
Target Synonym:NTRK1,Neurotrophic tyrosine kinase receptor type 1,TRK1-transforming tyrosine kinase protein,Tyrosine kinase receptor A,TRKA,Trk-A,Tyrosine kinase receptor,EC:2.7.10.1,High Affinity Nerve Growth Factor Receptor,EC 2.7.10,Neurotrophic Receptor Tyrosine Kinase 1,Neurotrophic Tyrosine Kinase, Receptor, Type 1,Tropomyosin-Related Kinase A,P140-TrkA,Gp140trk,MTC,TRK,Oncogene TRK,EC 2.7.10.1,TRK1,Receptor, trkA
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

Licensing

Project item Indications Research phase Cooperation demands
BDA202201 Cancer pain, chemotherapy-induced neuropathic pain, Kashin-Beck disease, diabetic neuralgia, interstitial cystitis, chronic low back pain. Phase Ⅰ/Ⅱa License-out or co-development

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TRA-H5253 Human Human TrkA / NTRK1 (192-402) Protein, Mouse IgG2a Fc Tag
TRA-H5253-structure
TRA-H5253-sds
TRA-H5259 Human Human TrkA / NTRK1 (33-417) Protein, Mouse IgG2a Fc Tag
TRA-H5259-structure
TRA-H5259-sds

Synonym Name

TrkA,NTRK1,MTC,TRK,TRKA,Trk-A

Background

Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand. Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Peritoneal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Adenoid Cystic; Thyroid Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Solid tumours; Glucagonoma; Multiple Myeloma; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Neoplasms; Glioblastoma; Colonic Neoplasms; Hemangiosarcoma; Carcinoma, Islet Cell; Insulinoma; Carcinoid Tumor; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms Details
Entrectinib NMS-E628; RXDX-101; RG-6268 Approved Nerviano Medical Sciences Rozlytrek, 罗圣全 Mainland China Solid tumours Roche (China) Holding Ltd 2019-06-18 Cholangiocarcinoma; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Melanoma; Brain metastases; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Hepatic Insufficiency; Colorectal Neoplasms; Brain Neoplasms; Sarcoma; Ovarian Neoplasms; Breast Neoplasms; Uveal melanoma; Central Nervous System Neoplasms; Neuroendocrine Tumors; Salivary Gland Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Renal Cell; Solid tumours; Head and Neck Neoplasms Details
Larotrectinib sulfate LOXO-101; ARRY-470; BAY-2757556 Approved Array Biopharma Vitrakvi, 维泰凯 Mainland China Solid tumours Bayer Healthcare Company Ltd 2018-11-26 Solid tumours; Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AK-1830 AK-1830 Phase 1 Clinical Array Biopharma Inflammation Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
SNA-125 CT-340; SNA-125 Phase 2 Clinical Sienna Biopharmaceuticals, Creabilis Pruritus; Psoriasis; Dermatitis, Atopic Details
VMD-928 VMD-928 Vm Oncology Details
XZP-5955 XZP-5955 Phase 2 Clinical Solid tumours Details
FCN-098 FCN-098; FCN098 Phase 1 Clinical Chongqing Fuchuang Pharmaceuticals Research Co Ltd, Fochon Pharmaceuticals Ltd Solid tumours; Neoplasms Details
Altiratinib DP-5164; DCC-2701; DCC-22701; T-678746713 Deciphera Details
Lestaurtinib SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 Kyowa Hakko Kirin Details
ACD-856 ACD-856 Alzecure Pharma Ab Details
VM-902A VM-902; VM-902A Vm Discovery Details
AZD-6918 AZD-6918 Astrazeneca Pharmaceutical Co Ltd Details
Pegcantratinib CT 327; SNA-120; CT 301/P; K-252a-PEG2K; Pegylated K252A Cephalon Details
TQB-3558 TQB-3558 Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Solid tumours Details
PLX-7486 PLX-7486; PLX7486-TsOH Daiichi Sankyo Co Ltd Details
PBI-200 Phase 2 Clinical Pyramid Biosciences Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms Details
VC-004 VC-004; VC 004; VC004 Phase 2 Clinical Jiangsu Weikeer Pharmaceutical Technology Co Ltd Solid tumours Details
HH-30134 HH-30134 Phase 1 Clinical ShangHai HaiHe Biopharma Co Ltd Solid tumours; Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message